The widespread development of nanocarriers to deliver chemotherapeutics to specific tumor
sites has been motivated by the lack of selective targeting during chemotherapy inducing …

The majority of advances in cancer therapy have been achieved based on developments in
public awareness, as well as novel diagnostic and therapeutic modalities. Treatment …

Nanoparticle (NP) stiffness has been shown to significantly impact circulation time and
biodistribution in anticancer drug delivery. In particular, the relationship between particle …

Smart nanomaterials, contrast nanoparticles and drug nanocarriers of advanced targeting
architecture were designed for various biomedical applications. Most of such agents …

Over the past two decades, polymersomes have been widely investigated for the delivery of
diagnostic and therapeutic agents in cancer therapy. Polymersomes are stable polymeric …

Synthetic polymers, biopolymers, and their nanocomposites are being studied, and some of
them are already used in different medical areas. Among the synthetic ones that can be …

Increasing attention is given to personalized tumour therapy, where α-emitters can
potentially play an important role. Alpha particles are ideal for localized cell killing because …

With the focus in the field of cancer nanomedicine shifting from direct tumor targeting to
modulation of the immune system, new opportunities arise for the employment of …

The oral route of administration for lipid-based nanocarriers is of immense importance for
the drugs having low bioavailability because of extensive first-pass metabolism. These drug …

A significant factor hindering the clinical translation of polymersomes as vesicular
nanocarriers is the limited availability of comparative studies detailing their interaction with …